Treatment Matched to Each Child's Risk for Infants and Young Children With Medulloblastoma

Official title: Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on September 15, 2026.

The short version

This study is testing whether treatment planned around each young child's own tumor and health can help.

Read our full plain-language summary

What the trial team says

This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number: NCT05535166
Stage of testing: Phase 2
Conditions studied: Medulloblastoma

Where it is running

This trial lists 10 sites.

California
- Lucille Packard Children's Hospital Stanford (Palo Alto)
Florida
- Orlando Health Arnold Palmer Hospital for Children (Orlando)
- St. Joseph's Children's Hospital (Tampa)
Michigan
- C.S. MOTT Children's Hospital, University of Michigan (Ann Arbor)
Minnesota
- Children's Hospital and Clinics of Minnesota (Minneapolis)
Tennessee
- St. Jude Children's Research Hospital (Memphis)
Texas
- UT Southwestern Medical Center/Harold C Simmons Comprehensive Cancer Center (Dallas)
- Cook Children's Medical Center (Fort Worth)
- Texas Children's Hospital (Houston)
Utah
- Primary Children's Hospital (Salt Lake City)

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.